Cargando…

Insights on the Quantitative Concurrent Fluorescence-Based Analysis of Anti-COVID-19 Drugs Remdesivir and Favipiravir

We hereby introduce a sensitive fast straightforward spectrofluorometric method for the estimation of remdesivir and favipiravir. The two drugs are prescribed in some regimens to treat COVID‐19 pandemic disease, which is caused by SARS‐CoV‐2. The method is based on the first derivative synchronous s...

Descripción completa

Detalles Bibliográficos
Autores principales: El-Awady, Mohamed, Elmansi, Heba, Belal, Fathalla, Shabana, Rasha abo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9244323/
https://www.ncbi.nlm.nih.gov/pubmed/35771341
http://dx.doi.org/10.1007/s10895-022-02998-z
_version_ 1784738499141828608
author El-Awady, Mohamed
Elmansi, Heba
Belal, Fathalla
Shabana, Rasha abo
author_facet El-Awady, Mohamed
Elmansi, Heba
Belal, Fathalla
Shabana, Rasha abo
author_sort El-Awady, Mohamed
collection PubMed
description We hereby introduce a sensitive fast straightforward spectrofluorometric method for the estimation of remdesivir and favipiravir. The two drugs are prescribed in some regimens to treat COVID‐19 pandemic disease, which is caused by SARS‐CoV‐2. The method is based on the first derivative synchronous spectrofluorimetry approach for the measurement of remdesivir and favipiravir. This was accomplished at 251 nm and 335 nm respectively using the first derivative order at delta lambda of 140 nm. A linear response with a correlation coefficient 0.9994 was achieved between the concentration and the derivative amplitudes in the ranges of 20.0–100.0 ng ml(−1) and 40.0–100.0 ng ml(−1) for remdesivir and favipiravir, respectively. The methods were validated for different parameters as stated by the pharmacopeial rules and were applied successfully for estimation of the studied drugs in their synthetic mixtures and in spiked human plasma samples. No significant difference was observed between the proposed and comparison methods as revealed from the analysis of data.
format Online
Article
Text
id pubmed-9244323
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-92443232022-06-30 Insights on the Quantitative Concurrent Fluorescence-Based Analysis of Anti-COVID-19 Drugs Remdesivir and Favipiravir El-Awady, Mohamed Elmansi, Heba Belal, Fathalla Shabana, Rasha abo J Fluoresc Research We hereby introduce a sensitive fast straightforward spectrofluorometric method for the estimation of remdesivir and favipiravir. The two drugs are prescribed in some regimens to treat COVID‐19 pandemic disease, which is caused by SARS‐CoV‐2. The method is based on the first derivative synchronous spectrofluorimetry approach for the measurement of remdesivir and favipiravir. This was accomplished at 251 nm and 335 nm respectively using the first derivative order at delta lambda of 140 nm. A linear response with a correlation coefficient 0.9994 was achieved between the concentration and the derivative amplitudes in the ranges of 20.0–100.0 ng ml(−1) and 40.0–100.0 ng ml(−1) for remdesivir and favipiravir, respectively. The methods were validated for different parameters as stated by the pharmacopeial rules and were applied successfully for estimation of the studied drugs in their synthetic mixtures and in spiked human plasma samples. No significant difference was observed between the proposed and comparison methods as revealed from the analysis of data. Springer US 2022-06-30 2022 /pmc/articles/PMC9244323/ /pubmed/35771341 http://dx.doi.org/10.1007/s10895-022-02998-z Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Research
El-Awady, Mohamed
Elmansi, Heba
Belal, Fathalla
Shabana, Rasha abo
Insights on the Quantitative Concurrent Fluorescence-Based Analysis of Anti-COVID-19 Drugs Remdesivir and Favipiravir
title Insights on the Quantitative Concurrent Fluorescence-Based Analysis of Anti-COVID-19 Drugs Remdesivir and Favipiravir
title_full Insights on the Quantitative Concurrent Fluorescence-Based Analysis of Anti-COVID-19 Drugs Remdesivir and Favipiravir
title_fullStr Insights on the Quantitative Concurrent Fluorescence-Based Analysis of Anti-COVID-19 Drugs Remdesivir and Favipiravir
title_full_unstemmed Insights on the Quantitative Concurrent Fluorescence-Based Analysis of Anti-COVID-19 Drugs Remdesivir and Favipiravir
title_short Insights on the Quantitative Concurrent Fluorescence-Based Analysis of Anti-COVID-19 Drugs Remdesivir and Favipiravir
title_sort insights on the quantitative concurrent fluorescence-based analysis of anti-covid-19 drugs remdesivir and favipiravir
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9244323/
https://www.ncbi.nlm.nih.gov/pubmed/35771341
http://dx.doi.org/10.1007/s10895-022-02998-z
work_keys_str_mv AT elawadymohamed insightsonthequantitativeconcurrentfluorescencebasedanalysisofanticovid19drugsremdesivirandfavipiravir
AT elmansiheba insightsonthequantitativeconcurrentfluorescencebasedanalysisofanticovid19drugsremdesivirandfavipiravir
AT belalfathalla insightsonthequantitativeconcurrentfluorescencebasedanalysisofanticovid19drugsremdesivirandfavipiravir
AT shabanarashaabo insightsonthequantitativeconcurrentfluorescencebasedanalysisofanticovid19drugsremdesivirandfavipiravir